BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » viacord

PerkinElmer Pairs Whole Genome Sequencing with Cord Blood and Tissue Banking

September 7, 2017 By Cade Hildreth (CEO) Leave a Comment

PerkinElmer Extends Clinical Whole Genome Sequencing Services

Provides Families a Novel, Personalized Approach to Managing their Health

September 07, 2017 08:15 AM EST — WALTHAM, Mass.–PerkinElmer, Inc., a global leader committed to innovating for a healthier world, expanded its Whole Genome Sequencing (WGS) services to families that preserve their cord blood and cord tissue with ViaCord. This launch follows the Company’s recent introduction of its clinical WGS services.

PerkinElmer Viacord Whole Genome Sequencing

Parents that choose ViaCord, PerkinElmer’s cord blood and cord tissue preservation business, now have the opportunity to benefit from a physician-ordered WGS test of their child’s DNA via a simple saliva test. The test examines a broad range of disease-related genes and provides diagnostic findings contributing to pediatric onset diseases. Additionally, the test reports on pharmacogenetic variants used to optimize certain drug selection.
[Read more…]

Filed Under: Cord Blood Tagged With: cord blood, genetic testing, PerkinElmer, viacord

Human Longevity Inc. Expands Role in Newborn Genome Sequencing with Strategic Acquisition of LifebankUSA from Celgene

January 28, 2016 By Cade Hildreth (CEO) Leave a Comment

Human Longevity Inc. Advances Leadership Role in Newborn Genome Sequencing with Strategic Acquisition of Stem Cell Banking from Celgene Cellular Therapeutics

In major news released today, Human Longevity, Inc. (HLI) announced that is is acquiring LifebankUSA, a cord blood, placental blood, and tissue bank owned by Celegene Cellular Therapeutics, a move that will position HLI to offer its newborn genome sequencing product in combination with stem cell banking services.

To learn more about the acquisition, read the full press release from Human Longevity, Inc. below.

Or, read our recent article exploring how this move will provide HLI with increased access to prenatal, neonatal, and maternal health markets, similar to the access that AMAG Pharmaceutical gained through its acquisition of Cord Blood Registry and PerkinElmer gained through its acquisition of ViaCord. [Read more…]

Filed Under: Cord Blood, HSCs, MSCs, Stem Cells Tagged With: CBR, cord blood, cord tissue, Human Longevity Inc., market news, press release, viacord

Human Longevity, Inc. to Expand Reach into Neonatal & Maternal Health Markets by Acquiring Celgene Owned LifebankUSA

January 28, 2016 By Cade Hildreth (CEO) Leave a Comment

Human Longevity, Inc. to Expand Reach into Neonatal & Maternal Health Markets by Acquiring Celegene Owned LifebankUSA

In major news released today, Human Longevity, Inc. (HLI) announced that is is acquiring LifebankUSA, a cord blood, placental blood, and tissue bank owned by Celgene Cellular Therapeutics.

Based in San Diego, CA, Human Longevity, Inc. is an innovative company that specializes in the use of whole genome sequence analysis, clinical imaging, and machine learning to extend health across a longer human lifespan. LifebankUSA, based in Cedar Knolls, NJ, is the “the only company that offers cord blood, placenta blood and tissue banking – and the first to release placenta-derived stem cells for a successful transplant.” Celgene Cellular Therapeutics (CCT), the parent company of LifeBankUSA, specializes in cell therapy and regenerative medicine products, using LifeBankUSA to source its cell therapy, organ and tissue products, several of which are now being explored in clinical trials (PDA001, PDA002, and others).

The move will position Human Longevity, Inc. to offers its newborn genome sequencing product in combination to its newly acquired stem cell banking services.
[Read more…]

Filed Under: Cord Blood, HSCs, MSCs, Press Releases, Stem Cells Tagged With: CBR, cord blood, cord tissue, Human Longevity Inc., placental, stem cells, viacord

ViaCord Finds Ultimate Solution to Cord Blood Marketing – Aligns with the World’s Largest Retailer of Maternity Clothing

January 25, 2016 By Cade Hildreth (CEO) Leave a Comment

ViaCord Finds Ultimate Solution to Cord Blood Marketing – Aligns with the World’s Largest Retailer of Maternity Clothing

An interesting partnership within the cord blood marketplace is between the second largest cord blood bank in the world, ViaCord, and the world’s largest designer and retailer of women’s maternity clothing, Destination Maternity. Headquartered in Philadelphia, Pennsylvania, USA, Destination Maternity operates 2,008 retail locations, including 625 stores, largely under the trade names Destination Maternity, Motherhood Maternity, and A Pea in the Pod.[1]

Based on the lack of competing offers, ViaCord appears to have exclusive rights to have its cord blood banking educational materials placed in the checkout bags of clients purchasing maternity items at Destination Maternity retail stores. [Read more…]

Filed Under: Cord Blood, HSCs, MSCs Tagged With: cord blood, market intelligence, market news, marketing, viacord

Who Are the Fastest Growth Cord Blood Banks?

January 25, 2016 By Cade Hildreth (CEO) Leave a Comment

While the global cord blood banking market has approximately 450 market participants, there are two fast growing cord blood banks that stand out among the competition. In this post, the fastest growth cord blood bank in the U.S and worldwide are featured, including their recent revenue metrics. The purpose of this analysis is to consider the strategies and actions being taken by these companies that have driven their rapid revenue growth over the past few years. [Read more…]

Filed Under: Cord Blood Tagged With: americord, china cord blood corporation, cord blood bank, Cord Blood Registry, CordLife, viacord

  • 1
  • 2
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.